دورية أكاديمية
أعرض في EDS

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil.

التفاصيل البيبلوغرافية
العنوان: Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil.
المؤلفون: Ranzani OT; Barcelona Institute for Global Health, ISGlobal, Universitat Pompeu Fabra (UPF), Barcelona, Spain.; Pulmonary Division, Heart Institute, Hospital das Clínicas, Faculdade de Medicina, São Paulo, SP, Brazil.; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., Hitchings MDT; Department of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA., de Melo RL; Secretaria Extraordinária de Enfrentamento à Covid-19, Ministério da Saúde, Brasília, DF, Brazil., de França GVA; Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília, DF, Brazil., Fernandes CFR; Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília, DF, Brazil., Lind ML; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA., Torres MSS; Municipal Health Secretary of Manaus, Manaus, AM, Brazil., Tsuha DH; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, MS, Brazil., David LCS; Pan American Health Organization, Brasilia, DF, Brazil., Said RFC; Pan American Health Organization, Brasilia, DF, Brazil., Almiron M; Pan American Health Organization, Brasilia, DF, Brazil., de Oliveira RD; State University of Mato Grosso do Sul, Dourados, MS, Brazil., Cummings DAT; Department of Biology, University of Florida, Gainesville, FL, USA.; Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA., Dean NE; Department of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Andrews JR; Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA., Ko AI; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.; Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brazil., Croda J; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. julio.croda@fiocruz.br.; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, MS, Brazil. julio.croda@fiocruz.br.; Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil. julio.croda@fiocruz.br.
المصدر: Nature communications [Nat Commun] 2022 Oct 06; Vol. 13 (1), pp. 5536. Date of Electronic Publication: 2022 Oct 06.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: COVID-19*/epidemiology , COVID-19*/prevention & control , COVID-19 Vaccines*, Adult ; BNT162 Vaccine ; Brazil/epidemiology ; Case-Control Studies ; Humans ; Vaccines, Inactivated
مستخلص: The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6-11.5) and 56.8% (95% CI, 56.3-57.3) in the period 8-59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9-80.7) and 86.0% (95% CI, 84.5-87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.
(© 2022. The Author(s).)
References: Nat Med. 2022 Apr;28(4):838-843. (PMID: 35140406)
Epidemiology. 2022 Jul 1;33(4):450-456. (PMID: 35384900)
Lancet. 2022 Mar 5;399(10328):924-944. (PMID: 35202601)
Clin Infect Dis. 2022 Apr 28;74(8):1382-1389. (PMID: 34282839)
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. (PMID: 35176007)
Cad Saude Publica. 2020 Apr 22;36(4):e00070120. (PMID: 32321075)
Int J Epidemiol. 2016 Dec 1;45(6):2052-2059. (PMID: 26979985)
N Engl J Med. 2022 Apr 21;386(16):1532-1546. (PMID: 35249272)
BMJ. 2022 Jun 13;377:e070102. (PMID: 35697361)
Am J Epidemiol. 2022 Mar 24;191(5):800-811. (PMID: 35081612)
Epidemiol Infect. 2019 Nov 27;147:e306. (PMID: 31774051)
N Engl J Med. 2022 May 12;386(19):1804-1816. (PMID: 35263534)
NPJ Vaccines. 2021 Apr 12;6(1):51. (PMID: 33846340)
N Engl J Med. 2021 Oct 7;385(15):1431-1433. (PMID: 34496195)
Nature. 2022 Jan;601(7893):311. (PMID: 35027748)
BMJ. 2021 Aug 20;374:n2015. (PMID: 34417194)
Nat Med. 2022 Mar;28(3):486-489. (PMID: 35051989)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
N Engl J Med. 2021 Oct 7;385(15):1355-1371. (PMID: 34496194)
N Engl J Med. 2021 Dec 9;385(24):e83. (PMID: 34614327)
Lancet Infect Dis. 2022 Apr;22(4):483-495. (PMID: 34890537)
Lancet Infect Dis. 2022 Oct;22(10):1435-1443. (PMID: 35850128)
Lancet. 2022 Feb 5;399(10324):521-529. (PMID: 35074136)
Epidemiology. 2020 Jan;31(1):43-64. (PMID: 31609860)
Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989)
JAMA. 2022 Feb 15;327(7):639-651. (PMID: 35060999)
Am J Epidemiol. 2016 Sep 1;184(5):345-53. (PMID: 27587721)
Nat Med. 2022 Mar;28(3):481-485. (PMID: 35051990)
Lancet Glob Health. 2022 Jun;10(6):e798-e806. (PMID: 35472300)
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826. (PMID: 34915551)
Epidemiology. 2021 Jul 1;32(4):508-517. (PMID: 34001753)
معلومات مُعتمدة: UL1 TR001863 United States TR NCATS NIH HHS
المشرفين على المادة: 0 (COVID-19 Vaccines)
0 (Vaccines, Inactivated)
N38TVC63NU (BNT162 Vaccine)
تواريخ الأحداث: Date Created: 20221006 Date Completed: 20221010 Latest Revision: 20230325
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9537178
DOI: 10.1038/s41467-022-33169-0
PMID: 36202800
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-022-33169-0